文献速递肿瘤 PET/CT

基于BMI的给药方案在18F-FDG全身PET/CT中降低注射活度并保持恒定图像质量

Can the BMI-based dose regimen be used to reduce injection activity and to obtain a constant image quality in oncological patients by 18F-FDG total-body PET/CT imaging?
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-06-29

该研究回顾性纳入78例肿瘤患者建立基于BMI的优化给药方案,并以38例前瞻性患者验证。结果显示肝脏SNR归一化值与BMI线性相关最强(R2=0.69),SNRL=14.0为可接受阈值,优化方案使各BMI组注射活度较第一队列降低64.8%–75.6%,且图像质量不随BMI增加而下降。

要点

  • 基于BMI的二次关系给药方案可降低18F-FDG注射活度。
  • 验证队列中各BMI组间SNRL无显著差异(p>0.05)。
  • SNRL=14.0被确定为满足临床图像质量的可接受阈值。

核心结论

  • 研究提出全身18F-FDG PET成像中注射活度与患者BMI呈二次关系,该方案可在降低注射活度的同时保持图像质量恒定并满足临床要求。

研究设计与样本

  • 第一队列回顾性纳入78例连续肿瘤患者(59.7 ± 13.7岁)行全身PET/CT,按WHO标准随机分入四个BMI组以建立方案。
  • 第二队列前瞻性纳入38例肿瘤患者用于验证优化方案。

主要发现

  • SNRnorm与BMI的线性拟合相关性最强(R2 = 0.69),优于其他患者依赖参数和拟合方法。
  • 定性评估表明SNRL值14.0为达到足够图像质量的可接受阈值。
  • 验证研究中SNRL不再随BMI增加而下降,不同BMI组间SNRL无显著差异(p > 0.05)。
  • 与第一队列相比,四个BMI组的注射活度分别降低75.6 ± 2.9%、72.1 ± 4.0%、67.1 ± 4.4%和64.8 ± 3.5%。

关键数值与推荐

  • 优化给药方案为二次关系:注射活度(MBq)= 39.2(MBq)/(- 0.03*BMI + 1.49)2。
  • SNRL值14.0作为满足临床图像质量的可接受阈值。

临床怎么用

  • 临床可依据患者BMI按二次关系公式计算18F-FDG注射活度,以在降低活度的同时维持恒定图像质量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: PET image quality is influenced by the patient size according to the current guideline. The study aimed to propose an optimized dose regimen to yield a constant image quality independent of patient habitus to meet the clinical needs. METHODS: A first patient cohort of 78 consecutive oncological patients (59.7 ± 13.7 years) who underwent a total-body PET/CT scan were retrospectively enrolled to develop the regimen. The patients were randomly distributed in four body mass index (BMI) groups according to the World Health Organization (WHO) criteria. The liver SNR (signal-to-noise ratio, SNRL) was obtained by manually drawing regions of interest (ROIs) and normalized (SNRnorm) by the product of injected activity and acquisition time. Fits of SNRnorm against different patient-dependent parameters were performed to determine the best correlating parameter and fit method. A qualitative assessment on image quality was performed using a 5-point Likert scale to determine the acceptable threshold of SNRL. Thus, an optimized regimen was proposed and validated by a second patient cohort consisted of prospectively enrolled 38 oncological patients. RESULTS: The linear fit showed SNRnorm had the strongest correlation (R2 = 0.69) with the BMI than other patient-dependent parameters and fit method. The qualitative assessment indicated a SNRL value of 14.0 as an acceptable threshold to achieve sufficient image quality. The optimized dose regimen was determined as a quadratic relation with BMI: injected activity (MBq) = 39.2 (MBq)/(- 0.03*BMI + 1.49)2. In the validation study, the SNRL no longer decreased with the increase of BMI. There was no significant difference of the image quality regarding the value of SNRL between different BMI groups (p > 0.05). In addition, the injected activity was reduced by 75.6 ± 2.9%, 72.1 ± 4.0%, 67.1 ± 4.4%, and 64.8 ± 3.5% compared with the first cohort for the four BMI groups, respectively. CONCLUSION: The study proposed a quadratic relation between the 18F-FDG injected activity and the patient's BMI for total-body 18F-FDG PET imaging. In this regimen, the image quality can maintain in a constant level independent of patient habitus and meet the clinical requirement with a reduced injected activity.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Xiao J, Yu H, Sui X, et al. Can the BMI-based dose regimen be used to reduce injection activity and to obtain a constant image quality in oncological patients by 18F-FDG total-body PET/CT imaging? Eur J Nucl Med Mol Imaging. 2021. PMID: 34185138. doi:10.1007/s00259-021-05462-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。